Authors
Shevchenko Yu.L.1, Kokorin V.V.1, 2
1 Pirogov National Medical and Surgical Center, Moscow
2 P.V. Mandryka Central Military Clinical Hospital, Moscow
Abstract
Amyloidoses are a group of conditions in which extracellular amyloid deposits (misfolded proteins) are present in the form of fibrils. A special Congo red stain is used for their detection. Amyloid deposits are frequently found in periarticular tissues across various disease entities, and their clinical interpretation is essential: transthyretin amyloid (ATTR) in the carpal tunnel may serve as an early marker of future ATTR cardiomyopathy; a persistent focus of chronic inflammation (e.g., chronic osteomyelitis) is associated with a risk of AA amyloidosis, including cardiac involvement; bacterial amyloids (curli) are considered potential factors that sustain inflammation and initiate amyloidogenesis in periarticular tissues. The concept of amyloid-associated conditions highlights the role of amyloid infiltration of periarticular tissues in the pathogenesis of enthesopathies and the impact of dysproteinosis on extracellular matrix properties and persistent enthesis remodeling.
The early detection of amyloid in surgical biopsies of periarticular tissue has practical significance: its presence should be considered as a “warning sign” requiring mandatory subtyping of the modern proteomic techniques (including LC-MS/MS). This approach improves the accuracy of early diagnosis of ATTR and AL variants of cardiac involvement prior to clinical manifestation of the disease and influences the further treatment strategy for the patient.
Keywords: periarticular tissues, enthesis, enthesopathy, angiogenesis, amyloid, collagenopathy, dysproteinosis, extracellular matrix.
References
1. Scott PP, Scott WWJr, Siegelman SS. Amyloidosis: an overview. Seminars in Roentgenology. 1986; 21(2): 103-112. doi: 10.1016/0037-198X(86) 90027-1.
2. Steiner I. The prevalence of isolated atrial amyloid. J Pathol. 1987; 153(4): 395-398. doi: 10.1002/path.1711530413.
3. Calkins E, Binette JP, Wright JR, Matsuzaki M, Ozdemir I. Some clinical observations on the nature of amyloid. Trans Am Clin Climatol Assoc. 1970; 81: 34-42.
4. Leung N, Nasr SH. 2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review. American Journal of Kidney Diseases. 2024; 84(3): 361-373. doi: 10.1053/j.ajkd.2024.01.530.
5. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature. 1959; 183(4669): 1202-1203. doi: 10.1038/1831202a0.
6. Bladen HA, Nylen MU, Glenner GG. The ultrastructure of human amyloid as revealed by the negative staining technique. Journal of Ultrastructure Research. 1966; 14(5): 449-459. doi: 10.1016/S0022-5320(66) 80075-8.
7. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification. International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016; 23(4): 209-213. doi: 10.1080/13506129.2016.1257986.
8. Buxbaum JN, Eisenberg DS, Fändrich M, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024; 31(4): 249-256. doi: 10.1080/13506129.2024.2405948.
9. Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of Internal Medicine. 2021; 289(3): 268-292. doi: 10.1111/joim.13169.
10. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021; 16: 1554-1568. doi: 10.1093/eurheartj/ehab072.
11. Picken MM. The Pathology of Amyloidosis in Classification: A Review. Acta Haematologica. 2020; 143(4): 322-334. doi: 10.1159/000506696.
12. Kholová I, Niessen HWM. Amyloid in the cardiovascular system: a review. Journal of Clinical Pathology. 2005; 58(2): 125-133. doi: 10.1136/jcp. 2004.017293.
13. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clinical Medicine (London). 2018; 18(S2): s30-s35. doi: 10.7861/clinmedicine.18-2-s30.
14. Snow AD, Wight TN. Proteoglycans in the pathogenesis of Alzheimer’s disease and other amyloidosis. Neurobiology of Aging. 1989; 10(5): 481-497. doi: 10.1016/0197-4580(89)90108-5.
15. Pepys MB, Rademacher TW, Amatayakul-Chantler S, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(12): 5602-5606. doi: 10.1073/pnas.91.12.5602.
16. Richards DB, Cookson LM, Barton SV, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine. 2018; 10(422): 3128. doi: 10.1126/scitranslmed.aan3128.
17. Sack GH. Jr. Serum amyloid A – a review. Molecular Medicine. 2018; 24(1): 46. doi: 10.1186/s10020-018-0047-0.
18. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine. 2016; 8(6): 595-608. doi: 10.15252/ emmm.201606210.
19. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews. 2011; 91(3): 795-826. doi: 10.1152/physrev.00042.2009.
20. Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. Journal of the American College of Cardiology. 2018; 72(17): 2040-2050. doi: 10.1016/j.jacc. 2018.07.092.
21. Debonnaire P, Claeys M, De Paepe P, et al. Prospective screening for transthyretin cardiac amyloidosis in spinal stenosis surgery patients: results of the CASS study. JACC: CardioOncology. 2023; 5(6): 836-838. doi: 10.1016/j.jaccao.2023.05.012.
22. Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. International Journal of Biochemistry & Cell Biology. 2003; 35(12): 1608-1613. doi: 10.1016/S1357-2725(03)00169-9.
23. Rapsinski GJ, Wynosky-Dolfi MA, Oppong GO, et al. Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infection and Immunity. 2015; 83(2): 693-701. doi: 10.1128/IAI.02370-14.
24. Mohr W. Amyloid deposits in the periarticular tissue. Zeitschrift für Rheumatologie. 1976; 35(11-12): 412-417.
25. Goffin YA, Thoua Y, Potvliege PR. Microdeposition of amyloid in the joints Annals of the Rheumatic Diseases. 1981; 40(1): 27–33. doi: 10.1136/ard.40.1.27.
26. Ladefoged C. Amyloid in osteoarthritic hip joints: deposits in relation to chondromatosis, pyrophosphate, and inflammatory cell infiltrate in the synovial membrane and fibrous capsule. Annals of the Rheumatic Diseases. 1983; 42(6): 659-664. doi: 10.1136/ard.42.6.659.
27. Ladefoged C. Amyloid deposits in the knee joint at autopsy. Annals of the Rheumatic Diseases. 1986; 45(8): 668-672. doi: 10.1136/ard.45.8.668.
28. Mitrovic DR, Stankovic A, Quintero M, Ryckewaert A. Amyloid deposits in human knee and hip joints. Rheumatology International. 1985; 5(2): 83-89. doi: 10.1007/BF00270302.
29. Rumpelt HJ, Braun A, Spier R, et al. Localized amyloid in the menisci of the knee joint. Pathology Research and Practice. 1996; 192(6): 547-551. doi: 10.1016/S0344-0338(96)80104-X.
30. Savadogo B, Fahed H, Sellam J, et al. AA amyloidosis in inflammatory joint diseases: a systematic review. Seminars in Arthritis and Rheumatism. 2025; 74: 152762. doi: 10.1016/j.semarthrit.2025.152762.
31. Niggemeyer O, Steinhagen J, Deuretzbacher G, et al. Amyloid deposition in osteoarthritis of the hip. Archives of Orthopaedic and Trauma Surgery. 2011; 131(5): 637-643. doi: 10.1007/s00402-010-1187-z.
32. Miller AL, Bessho S, Grando K, Tükel Ç. Microbiome or infections: amyloid-containing biofilms as a trigger for complex human diseases. Frontiers in Immunology. 2021; 12: 638867. doi: 10.3389/fimmu.2021.638867.
33. Miller AL, Pasternak JA, Medeiros NJ, et al. In vivo synthesis of bacterial amyloid curli contributes to joint inflammation during S. Typhimurium infection. PLOS Pathogens. 2020; 16(7): e1008591. doi: 10.1371/ journal.ppat.1008591.
34. Benjamin M, Moriggl B, Brenner E, et al. The “enthesis organ” concept: why enthesopathies may not present as focal insertional disorders. Arthritis & Rheumatism. 2004; 50(10): 3306–3313. doi: 10.1002/art.20566.
35. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circulation Research. 2021; 128(10): 1554-1575. doi: 10.1161/CIRCRESAHA.121.318187.
36. Prummel KD, Nieuwenhuize S, Mosimann C. The lateral plate mesoderm. Development. 2020; 147(12): 175059. doi: 10.1242/dev.175059.
37. Brent AE, Schweitzer R, Tabin CJ. A somitic compartment of tendon progenitors. Cell. 2003; 113(2): 235-248. doi: 10.1016/S0092-8674(03)00268-X.
38. Franssen C, González Miqueo A. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Netherlands Heart Journal. 2016; 24(4): 259-267. doi: 10.1007/s12471-016-0812-z.
39. Brower GL, Janicki JS. The relationship between myocardial extracellular matrix remodeling and ventricular function. European Journal of Cardio-Thoracic Surgery. 2006; 30(4): 604-610. doi: 10.1016/j.ejcts.2006.07.006.
40. Shevchenko YuL. Immobiliziruyushchiy interstitsial’nyy fibroz serdtsa. Chast’ 1. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N. I. Pirogova. 2022; 17(2): 4-10. (In Russ.) doi: 10.25881/20728255_2022_17_2_4.
41. Shevchenko YuL, Ul’bashev DS. Immobiliziruyushchiy interstitsial’nyy fibroz serdtsa. Chast’ 2. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N. I. Pirogova. 2022; 17(3): 4-10. (In Russ.) doi: 10.25881/ 20728255_2022_17_3_4.
42. Shevchenko YuL, Plotnitskiy AV, Sudilovskaya VV, Dubova EA, Ul’bashev DS. Morfologiya i markery immobiliziruyushchego interstitsial’nogo fibroza serdtsa Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N. I. Pirogova. 2022; 17(3): 84-93. (In Russ.) doi: 10.25881/20728255_2022_17_3_84.
43. Shevchenko YuL, Plotnitskiy AV, Ul’bashev DS. Pervichnyy i vtorichnyy (indutsirovannyy) immobiliziruyushchiy interstitsial’nyy fibroz serdtsa. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N. I. Pirogova. 2022; 17(4 Pt. 2): 136-142. (In Russ.) doi: 10.25881/20728255_2022_17_4_2_136.
44. Shevchenko YuL, Plotnitsky AV, Ulbashev DS. Immobilizing interstitial cardiac fibrosis. Cardiology Research. 2023; 14(2): 123-132. doi: 10.14740/cr1467.
45. Shevchenko YuL. Immobiliziruyushchiy interstitsial’nyy fibroz serdtsa kak samostoyatel’naya prichina razvitiya khronicheskoy serdechnoy nedostatochnosti. Ekologiya i razvitie obshchestva. 2024; 3-4(43): 42-54. (In Russ.)
46. Tallquist MD, Molkentin JD. Redefining the identity of cardiac fibroblasts. Nature Reviews Cardiology. 2017; 14(8): 484-491. doi: 10.1038/nrcardio. 2017.57.
47. Killian ML. Growth and mechanobiology of the tendon-bone enthesis. Seminars in Cell & Developmental Biology. 2022; 123: 64-73. doi: 10.1016/j.semcdb.2021.07.015.
48. Schelbert EB, Butler J, Diez J. Why Clinicians Should Care About the Cardiac Interstitium. JACC: Cardiovascular Imaging. 2019; 12(11, Pt. 2): 2305-2318. doi: 10.1016/j.jcmg.2019.04.025.
49. Pucci A, Aimo A, et al. Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. Journal of the American Heart Association. 2021; 10(20): e020358. doi: 10.1161/JAHA.120.020358.
50. Lavatelli F, Marchese L, Mangione PP, et al. Role of extracellular space and matrix remodeling in cardiac amyloidosis. Matrix Biology. 2025; 140: 100-112. doi: 10.1016/j.matbio.2025.07.004.
51. Schulte T, Chaves-Sanjuan A, Speranzini V, et al. Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis. Nature Communications. 2024; 15(1): 6359. doi: 10.1038/ s41467-024-50686-2.
52. Lewkowicz E, Jayaraman S, Gursky O. Molecular basis for non-invasive diagnostics of cardiac amyloids using bone tracers. Biomaterials Science. 2024; 12: 4275-4282. doi: 10.1039/D4BM00816B.
53. Colombat M, Gaspard M, Camus M, et al. Mass spectrometry-based proteomics in clinical practice amyloid typing: state-of-the-art from a French nationwide cohort. Haematologica. 2022; 107(12): 2983-2987. doi: 10.3324/ haematol.2022.281431.
54. Biolo A, Ramamurthy S, Connors LH, et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circulation: Heart Failure. 2008; 1(4): 249-257. doi: 10.1161/CIRCHEARTFAILURE.108.788687.
55. Huang X, Yang N, Fiore VF, et al. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. American Journal of Respiratory Cell and Molecular Biology. 2012; 47(3): 340-348. doi: 10.1165/rcmb.2012-0050OC.
56. Dasari S, Theis JD, Vrana JA, et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clinic Proceedings. 2020; 95(9): 1852-1864. doi: 10.1016/j.mayocp.2020.06.029.
57. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114(24): 4957-4959. doi: 10.1182/blood-2009-07-230722.
58. Wininger AE, Phelps BM, Le JT, et al. Musculoskeletal pathology as an early warning sign of systemic amyloidosis: a systematic review of amyloid deposition and orthopedic surgery. BMC Musculoskeletal Disorders. 2021; 22(1): 51. doi: 10.1186/s12891-020-03912-z.
59. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. The Lancet. 2016; 387(10038): 2641-2654. doi: 10.1016/S0140-6736(15)01274-X.
60. Kim AB, Xiao Q, Yan P, et al. Chimeric antigen receptor macrophages target and resorb amyloid plaques. JCI Insight. 2024; 9(6): e175015. doi: 10.1172/jci.insight.175015.
